A breakthrough medical study published in a leading peer-reviewed scientific journal on Thursday demonstrated that a novel single-dose DNA-based epigenetic silencing therapeutic achieved an unprecedented forty-seven percent durable reduction in circulating low-density lipoprotein cholesterol in preclinical animal models. The experimental biologic targets hepatic genes responsible for dyslipidemia without introducing permanent breaks in native genomic DNA.
Biomedical researchers conducting the multi-center translational trial explained that the therapeutic utilizes precision synthetic DNA oligonucleotides paired with proprietary lipid nanoparticles to silence the PCSK9 expression pathway. Laboratory testing confirmed sustained therapeutic efficacy over a six-month observation period following a single administration, accompanied by a favorable safety profile with zero liver enzyme abnormalities or adverse immune triggers.
Cardiologists hailed the findings as a revolutionary prospective therapy for patients suffering from severe familial hypercholesterolemia who cannot tolerate standard statin regimens or require frequent antibody injections. The scientific consortium confirmed that preparatory work for Phase I human clinical trials has commenced, with regulatory submissions scheduled for late next year.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://school.edusaint.in/news/school-assembly-news-headlines-17-september-2026